Glofitamab, a CD20/CD3 bispecific antibody, in the treatment of R/R DLBCL

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & moreПодробнее

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & more

Bispecific Antibody Treatment in Non-Hodgkin Lymphoma: Glofitamab - Blood Cancers OncTalk 2023Подробнее

Bispecific Antibody Treatment in Non-Hodgkin Lymphoma: Glofitamab - Blood Cancers OncTalk 2023

The role of bispecific antibodies in the treatment landscape for R/R DLBCLПодробнее

The role of bispecific antibodies in the treatment landscape for R/R DLBCL

Phase II study of glofitamab in patients with R/R LBCLПодробнее

Phase II study of glofitamab in patients with R/R LBCL

Impact of TMTV on PFS following glofitamab treatment in R/R DLBCLПодробнее

Impact of TMTV on PFS following glofitamab treatment in R/R DLBCL

The benefits of glofitamab in R/R DLBCL post-CAR-T therapyПодробнее

The benefits of glofitamab in R/R DLBCL post-CAR-T therapy

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphomaПодробнее

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

Bispecific antibodies for R/R aggressive B-cell lymphomasПодробнее

Bispecific antibodies for R/R aggressive B-cell lymphomas

Glofitamab in R/R DLBCL: updated safety and efficacy dataПодробнее

Glofitamab in R/R DLBCL: updated safety and efficacy data

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapyПодробнее

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapy

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCLПодробнее

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCL

Updates in bispecifics for DLBCL from ASH: glofitamab, odronextamab, epcoritamab & mosunetuzumabПодробнее

Updates in bispecifics for DLBCL from ASH: glofitamab, odronextamab, epcoritamab & mosunetuzumab

Glofitamab as a single agent in heavily pretreated patients with DLBCLПодробнее

Glofitamab as a single agent in heavily pretreated patients with DLBCL

Glofitamab and polatuzumab vedotin in DLBCLПодробнее

Glofitamab and polatuzumab vedotin in DLBCL

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCLПодробнее

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL

The important role of bispecific antibodies in the future treatment of R/R DLBCLПодробнее

The important role of bispecific antibodies in the future treatment of R/R DLBCL

Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCLПодробнее

Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCL

Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell LymphomaПодробнее

Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma

ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter's transformationПодробнее

ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter's transformation

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?Подробнее

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?